Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Mechanism Controlling Neuronal Migration Discovered By St. Jude Scientists
The molecular machinery that helps brain cells migrate to their correct place in the developing brain has been identified by scientists at St. Jude Children"s Research Hospital. The finding offers new insight into the forces that drive brain organization in developing fetuses and children during their first years. Disruption of this brain-patterning machinery can cause epilepsy and mental retardation and understanding its function could give new insight into such disorders.
generic viagra online
Diabetes Drug Shows MS Potential
A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss.
News of the day
Renowned Surgeon Examines Our Most Significant Contributions To Surgery - From Crude Procedures To Precision Operations
As a result of the scientific advances and medical innovations made in the twentieth century, the United States today occupies an established and unchallenged leading role in the field of surgery. Renowned surgeon Seymour I. Schwartz, MD, gives a sweeping history of American surgical practice in "Gifted Hands: America"s Most Significant Contributions To Surgery" (Prometheus Books). He describes how surgery in the United States has advanced from the comparatively crude practices of pioneering physicians in the pre-Columbian and colonial eras to its current level of preeminence in scientific surgery today.
Diagnostics

Foresight Biotherapeutics Announces Positive Results From An Open Label Pilot Study In Patients With Viral Conjunctivitis

Foresight Biotherapeutics, Inc. announced completion of a multi-center open-label pilot study of FST100 in the treatment of viral conjunctivitis. FST-100 is a novel formulation of dexamethasone that includes povidone iodine. The trial studied patients with clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by the RPS Adeno Detector® (RPS). Patients were enrolled in a single arm utilizing FST-100 topical ophthalmic suspension given 4 times daily for 5 days. The RPS Adeno Detector® test was performed at baseline and at each visit along with conjunctival swabs for adenoviral titers by quantitative PCR (qPCR) and cell culture with confirmatory immunoflourescence (CC-IFA). The primary endpoint of the study was clinical resolution of conjunctival injection and conjunctival discharge. These signs were scored on a scale from zero to three. Secondary endpoints included reduction of viral titers measured by qPCR and eradication of infectious virus determined by CC-IFA. FST-100 met the primary endpoint of the study by demonstrating complete resolution of conjunctivitis signs (a score of zero) in all eyes completing the study. One patient was lost to follow-up. In all RPS positive eyes with confirmed viral infection by qPCR and CC-IFA clinical symptoms resolved within 72 hours. All eyes completing the study with detectable adenovirus by qPCR demonstrated significant reduction in viral titers by 48-96 hours and the majority demonstrated elimination of infectivity by CC-IFA by 72-96 hours. There were no adverse events in the study. Lead investigator Jesse Pelletier, M.D. commented, "We are excited about this preliminary data and look forward to enrolling patients in a larger controlled clinical study. Currently, there are no drugs approved for the treatment of viral conjunctivitis and it is certainly an area of unmet medical need." Foresight Biotherapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009